ResearchHub Text Logo
Home
Live
new
RH Journal
ResearchCoin
Grants
Funding
Browse
Journals
Hubs
Tools
Lab Notebook
Beta
Reference Manager
Resources
Verify IdentityVerified
CommunitySupportAbout
TermsPrivacyIssuesDocs
Paper
RH Logo
RH LogoRH Logo
Paper
0
Paper
Conversation
Grants
Reviews
Document
Submit new version
Download
Flag content
0

Empagliflozin improves pressure-overload-induced cardiac hypertrophy by inhibiting the canonical Wnt/β-catenin signaling pathway

Pharmacology
Internal Medicine
Cell Biology
Show More
Save
TipTip
Document
Submit new version
Download
Flag content
0
TipTip
Save
Document
Submit new version
Download
Flag content
Paper
Conversation
Grants
Reviews

Abstract

Empagliflozin (EMPA) is an SGLT-2 inhibitor that can control hyperglycemia. Clinical trials have indicated its cardio-protective effects against cardiac remodeling in diabetes or non-diabetes patients. However, the underlying molecular mechanisms of EMPA's cardio-protective effects remain elusive.

Paper PDF

Empty State
This PDF hasn't been uploaded yet.
Do not upload any copyrighted content to the site, only open-access content.
or